PD-L1 Expression in Urothelial Bladder Carcinoma

  • Research type

    Research Study

  • Full title

    Immunohistochemical Investigation of PD-L1 Expression in Staging Urothelial Bladder Cancer

  • IRAS ID

    216750

  • Contact name

    Helen Armitage

  • Contact email

    helen.armitage@york.nhs.uk

  • Sponsor organisation

    University of Greenwich

  • Duration of Study in the UK

    0 years, 5 months, 13 days

  • Research summary

    The aim of this project is to investigate the expression of PD-L1 (programmed cell death ligand-1) in High Grade 2 (stages pTa, pT1 and pT2) and grade 3 (stages pTa, pT1 and pT2) urothelial bladder carcinoma. The different tumour stages are benign (pTa) to Malignant (pT2) which will be stained with the antibody PD-L1 . This will allow the identification of positive tumour cells staining with this antibody at different stages of the two tumour grades. The grade of tumour has been selected with regard to WHO criteria of 1973 and 2004.
    Archive tissue left over after diagnosis will be used for the 3 different stages of grade 2 and grade 3 urothelial bladder carcinoma and will be approximately 3um in size. Control tissue will be selected from archived material after diagnosis and will be normal and tumour sections which will allow the level of PD-L1 staining to be examined as weak, moderate or strong staining.
    The aim of this project is to investigate whether the high grade tumours at high stages (pT2) are positive for PD-L1 and those that are at a low stage (pTa) either do not stain or have very weak staining. The information from this study will provide an insight to prognosis at different stages and grades of urothelial bladder carcinoma and in the future may provide information on the possibility for immunotherapy for PD-L1 positive high grade tumours which is currently not available however it is available for certain cases of metastatic urothelial carinoma in the USA recently FDA approved. This project will also provide information on how the tumour is progressing and whether it is using the cell signalling PD-L1 pathway to grow and invade the surrounding tissues.

  • REC name

    South Central - Oxford B Research Ethics Committee

  • REC reference

    17/SC/0045

  • Date of REC Opinion

    24 Jan 2017

  • REC opinion

    Favourable Opinion